Research programme: specific progesterone receptor modulators - Eledon Pharmaceuticals
Alternative Names: CP 8661; CP 8668; CP 8816; CP 8863Latest Information Update: 07 Jan 2021
Price :
$50 *
At a glance
- Originator Meiji Seika Kaisha
- Developer Eledon Pharmaceuticals
- Class Small molecules
- Mechanism of Action Progesterone receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Uterine diseases
Most Recent Events
- 04 Jan 2021 Novus Therapeutics is now called Eledon Pharmaceuticals
- 10 May 2017 Tokai Pharmaceuticals has merged with Otic Pharma and subsequently changed its name to Novus Therapeutics
- 09 Jun 2009 Programme licensed to Tokai Pharmaceuticals worldwide